August 1, 2018 – Charleston, SC, USA – RichSource Stem Cells, Inc. (RichSource), a leader in the business development and distribution of human tissue allograft combination products and membranes, announced today its own brand product line: RICHGEN. With the introduction of this breakthrough line, the industry is no longer limited to single material post-birth, multipotent cellular products. Available throughout the U.S., the RICHGEN product line is backed by an experienced nationwide team of RichSource Area Vice Presidents who can educate, train and provide support to physician practices and networks. Additionally, RichSource’s simplified and more effective treatment protocols helps to optimize practices and patient results. [Read more…]
Fresenius Medical Care achieves preclinical milestone in its regenerative medicine program for chronic kidney disease
July 30, 2018 – Fresenius Medical Care, the world’s largest provider of dialysis products and services, announced today that its subsidiary Unicyte AG has achieved a key preclinical milestone in its regenerative medicine program for chronic kidney disease. The company was able to confirm a disease modifying potential for its proprietary nano-Extracellular Vesicles (“nEVs” are stem cell-derived particles that support communication between cells) in a second preclinical model of chronic kidney disease. [Read more…]
Irvine Scientific Introduces Chemically-Defined Natural Killer Cell Expansion Medium for Immunotherapy & Translational Research Applications
The first chemically-defined, animal component-free cell culture medium for natural killer (NK) cells
July 2018, Santa Ana, Calif. — Irvine Scientific, an industry leader in the development and manufacture of cell culture media, announced the introduction of PRIME-XV® NK Cell CDM— the first commercially available chemically-defined (CDM), animal component-free (ACF) medium for the ex vivo expansion of NK cells. The advanced medium delivers natural killer (NK) cell expansion while preserving NK cell potency and functionality. [Read more…]
Two-Year-Old Emirati Boy Saves Older Brother with Stem Cells Stored with CryoSave Arabia
Dubai, UAE, July 2018 – Hamad Alyaarbi an eight-year-old Emirati boy who suffers from the debilitating condition Sickle Cell Anemia, has had his disease cured thanks to the use of stem cells from his younger brother, Abdullah, that were stored by CryoSave Arabia. At the beginning of 2017 Hamad’s parents had made the decision to use the cord blood stem cells from his younger brother, Abdullah, for a transplant to try and save his life. The transplant took place on 23rd June 2017, and almost a year later, Hamad is now completely cured and living a happy, healthy life, disease-free. [Read more…]
Steminent Announces FDA Approval of IND for Phase II Clinical Trial of Stemchymal® SCA in the Treatment of Spinocerebellar Ataxia
San Diego, CA, USA, July 18th, 2018 – Steminent Biotherapeutics Inc. (“Steminent” or “Company”) a private, clinical-stage cell-therapy company with offices in Taiwan, San Diego and Shanghai, is pleased to announce that the United States Food and Drug Administration (“FDA”) has raised no objections to the Company’s Investigational New Drug (“IND”) application. This allows the Company to initiate its Phase II clinical trial for polyglutamine spinocerebellar ataxia (“PolyQ SCA”) to enroll patients at clinical sites in the United States. This is a key milestone for the Company’s international Stemchymal® SCA Phase II clinical trials program. [Read more…]
- « Previous Page
- 1
- …
- 104
- 105
- 106
- 107
- 108
- …
- 117
- Next Page »